Can Multaq Cause Bradycardia?
Yes, dronedarone (Multaq) can cause bradycardia, occurring in approximately 3% of patients compared to 1% with placebo. This is a recognized adverse effect documented in both FDA labeling and clinical trials.
Evidence from FDA Drug Label and Clinical Trials
The FDA label for Multaq explicitly lists bradycardia as a cardiac adverse reaction occurring in 3% of patients treated with dronedarone 400 mg twice daily versus 1% in placebo groups 1. In the landmark ATHENA trial involving over 4,600 patients, dronedarone demonstrated higher rates of bradycardia compared to placebo 2.
Mechanism of Bradycardia
Dronedarone's bradycardic effect is primarily mediated through inhibition of the If (funny current) in the sinoatrial node, not through beta-blockade or calcium channel antagonism 3. This mechanism is similar to ivabradine and explains why dronedarone reduces heart rate without significantly affecting blood pressure or contractility in most patients.
Clinical Context and Risk Factors
High-Risk Situations for Bradycardia
Multiple guidelines identify specific scenarios where bradycardia risk is heightened:
- Pre-existing sinus or AV node dysfunction - Dronedarone should be avoided in patients with high-degree AV conduction disorders unless a pacemaker is present 4
- Concomitant use with other rate-controlling agents - The combination of dronedarone with beta-blockers or calcium channel blockers potentiates bradycardic effects 5
- Digoxin co-administration - Digoxin can potentiate dronedarone's electrophysiologic effects on AV node conduction 1
Management Strategy
When initiating dronedarone in patients requiring concurrent rate control:
- Start with low doses of beta-blockers or calcium channel blockers initially
- Increase doses only after ECG verification of good tolerability 1
- Monitor ECG at baseline and 48-72 hours after initiation 4
- Consider discontinuing digoxin or halving the dose if continuation is necessary 1
Important Contraindications
Dronedarone is absolutely contraindicated in:
- Permanent atrial fibrillation (increased mortality risk) 6, 7, 8
- NYHA Class IV heart failure or recent decompensation with LVEF <40% 9, 4
- Advanced sinus or AV nodal disease without pacemaker 5
Clinical Pearls
Bradycardia from dronedarone can be exacerbated by any antiarrhythmic agent affecting sinus or AV node function 5. If symptomatic bradycardia develops, the drug should be discontinued or permanent pacemaker implantation considered 5.
The 2020 Canadian guidelines emphasize that while dronedarone is generally safe and well-tolerated, it should be avoided in patients with high-degree AV conduction disorders due to this bradycardic potential 4.
The bradycardic effect is dose-dependent and reversible upon discontinuation, with dronedarone's relatively short half-life (approximately 24 hours) allowing for rapid resolution of symptoms 4.